Related Experiment Video
Updated: Dec 31, 2025
10:45
Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
Published on: May 25, 2017
15.0K
Alcohol-related liver diseases
Jiří Ehrmann1, Ondřej Urban1, Pavol Dvoran1
1Department of Internal Medicine II - Gastroenterology and Geriatrics, Faculty of Medicine, Palacky University Olomouc and University Hospital, Olomouc, Czech Republic.
Central European Journal of Public Health
|January 5, 2020
Summary
The European Association for the Study of the Liver updated guidelines for alcohol-related liver disease management. Prevention of alcohol use disorder is now strongly emphasized across all healthcare stages.
Area of Science:
- Hepatology
- Public Health
- Clinical Practice Guidelines
Background:
- Alcohol-related liver disease (ARLD) is a significant global health concern.
- Previous guidelines from 2012 require updates to reflect current understanding and best practices.
- The European Association for the Study of the Liver (EASL) provides essential clinical guidance.
Purpose of the Study:
- To present the updated EASL clinical practice guidelines for the management of alcohol-related liver disease.
- To highlight key changes from the previous 2012 guidelines, including new terminology.
- To emphasize the critical role of prevention strategies for alcohol use disorder.
Main Methods:
- This article is a narrative review of the EASL clinical practice guidelines.
- It synthesizes information from the latest EASL recommendations on ARLD.
- The review focuses on changes in terminology and management approaches.
Main Results:
- A significant update is the adoption of new terminology for alcohol-related liver diseases.
- There is a heightened focus on the prevention of alcohol use disorder.
- Prevention strategies are recommended for integration across all levels of public healthcare.
Conclusions:
- The updated EASL guidelines offer a revised framework for managing alcohol-related liver disease.
- Emphasis on prevention of alcohol use disorder is a key advancement in public health strategy.
- Healthcare professionals should adopt the new terminology and prevention-focused approach.
More Related Videos
Related Concept Videos
01:26Diseases of the Liver and Gallbladder
1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
140
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
140
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
174
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
174
01:24Chronic Pancreatitis I: Introduction
628
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
628
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
211
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
211
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
162
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
162